NCT01077505View on ClinicalTrials.gov

An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

March 15, 2010

Primary Completion Date

November 24, 2010

Study Completion Date

November 24, 2010

Conditions

Diabetes Mellitus, Type 2

Interventions

BIOLOGICAL

albiglutide

albiglutide 50mg weekly subcutaneous injection

DRUG

Oral contraceptive (Brevicon)

Oral contraceptive (Brevicon)

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01077505 - An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide . | Biotech Hunter | Biotech Hunter